Bolivia (Plurinational State of)Tuberculosis profile
Population  2015 11 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.34 (0.22–0.5) 3.2 (2–4.6)
Mortality (HIV+TB only) 0.17 (0.1–0.26) 1.6 (0.93–2.4)
Incidence  (includes HIV+TB) 13 (8.1–18) 117 (76–167)
Incidence (HIV+TB only) 0.55 (0.35–0.79) 5.1 (3.3–7.4)
Incidence (MDR/RR-TB)** 0.5 (0.25–0.74) 4.7 (2.3–6.9)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.71 (0.26–1.2) 4.2 (1.7–6.6) 4.9 (2–7.8)
Males 0.83 (0.49–1.2) 6.9 (4.7–9) 7.7 (5.2–10)
Total 1.5 (0.99–2.1) 11 (8.3–14) 13 (8.1–18)
TB case notifications, 2015  
Total cases notified 7 893
Total new and relapse 7 789
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 83%
          - % pulmonary 79%
          - % bacteriologically confirmed among pulmonary 91%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 62% (43–96)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.04 (0.03–0.07)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 281 4%
          - on antiretroviral therapy 182 65%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  240
(150–330)
Estimated % of TB cases with MDR/RR-TB 3% (1.5–4.6) 12% (9.5–16)  
% notified tested for rifampicin resistance 6% 93% 1 007
MDR/RR-TB cases tested for resistance to second-line drugs   10
Laboratory-confirmed cases MDR/RR-TB: 79, XDR-TB: 7
Patients started on treatment **** MDR/RR-TB: 41, XDR-TB: 1
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 83% 8 079
Previously treated cases, excluding relapse, registered in 2014 57% 122
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013 61% 44
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (93–100)
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data